Results 71 to 80 of about 2,752 (194)

Chronic treatment with indacaterol and airway response to salbutamol in stable COPD [PDF]

, 2013
SummaryTolerance to both the bronchoprotective effect, and, to a lesser extent, the bronchodilator activity, occurs with all inhaled β2-agonists. Assumed the importance of this topic and the lack of a clinical evaluation specifically designed to assess ...
Picciolo, S, Matera, M, Cazzola, M, Segreti, Andrea, Rogliani, Paola, Segreti, A, Ruggeri, Paolo, Cazzola, Mario, Rogliani, P, Picciolo, Stefano, Proietto, A, Ruggeri, P, Proietto, Alfio, Matera, Maria Gabriella, Matera, M.   +14 more
core   +1 more source

Comparative efficacy of indacaterol 150 µg and 300 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis

International Journal of COPD, 2011
Shannon Cope1, Gorana Capkun-Niggli2, Rupert Gale3, José R Jardim4, Jeroen P Jansen11Mapi Values, Boston, MA, USA; 2Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland; 3Novartis Horsham Research Centre, Horsham, UK;
Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP   +4 more
doaj  

Unveiling the amplified oxidase-mimetic activity of MnCoO nanosheets for the ultra-sensitive determination of the long-acting beta-adrenoceptor agonist indacaterol

Talanta Open
The ability to determine indacaterol in different matrices is critical for the medication adherence assessment. In the current approach, we introduce a pioneering colorimetric detection approach for the sensitive quantitation of indacaterol using ...
Amal A. El-Masry, Heba Elmansi, Nahed El-Enany   +2 more
doaj   +1 more source

Efficacy and safety of carvedilol in combination with bronchodilators in patients with CHF of ischemic origin and COPD.

Клиническая практика, 2019
Objective. To study the effectiveness of carvedilol, tiotropium bromide and indacaterol in complex therapy on clinical and functional parameters in patients with CHF of ischemic origin in combination with COPD. Material and methods. The study included
Vladimir V. Evdokimov, A. G. Evdokimova, E. N. Yushchuk   +2 more
doaj   +1 more source

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

International Journal of Chronic Obstructive Pulmonary Disease, 2014
Addition of a second bronchodilator from a different pharmacological class may benefit patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) whose symptoms are insufficiently controlled by bronchodilator monotherapy. GLOW6 evaluated the efficacy and safety of once-daily coadministration of the long-acting β2-agonist indacaterol (
Vincken,Walter, Aumann,Joseph, Chen,Hungta, Henley,Michelle, McBryan,Danny, Goyal,Pankaj   +5 more
openaire   +5 more sources

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review

International Journal of COPD, 2014
Charlotte Suppli UlrikDepartment of Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Hvidovre, DenmarkBackground and aim: Long-acting bronchodilators are the preferred option for maintenance therapy of patients with chronic ...
Ulrik CS
doaj  

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US

International Journal of COPD, 2018
Krithika Rajagopalan,1 Lisa Bloudek,2 Jessica Marvel,3 Carole Dembek,1 Abhishek Kavati3 1Sunovion Pharmaceuticals Inc., Marlborough, MA 01752, USA; 2Curta Inc., Seattle, WA 98116, USA; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA ...
Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A   +4 more
doaj  

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide

Patient Preference and Adherence, 2019
Erminia Ridolo,1 Irene Pellicelli,1 Bruna Gritti,2 Cristoforo Incorvaia2 1Allergy and Clinical Immunology, Medicine and Surgery Department, University of Parma, Parma, Italy; 2Cardiac/Pulmonary Rehabilitation Unit, ASST Pini-CTO, Milan, Italy Abstract:
Ridolo E, Pellicelli I, Gritti B, Incorvaia C   +3 more
doaj  

Indacaterol 75 µg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective

Therapeutic Advances in Respiratory Disease, 2013
Chronic obstructive pulmonary disease (COPD) is a progressive disease in which patients become increasingly disabled by their symptoms and limited in their activities.
Edward M. Kerwin, James Williams
doaj   +1 more source

Indacaterol versus Tiotropium on FEV1 at 12 weeks.

, 2013
Indacaterol versus Tiotropium on FEV1 at 12 weeks.
Polly H. X. Ma (115746), Wilson W. S. Tam (288770), David S. C. Hui (341922), Jin Ling Tang (445464), Vincent C. H. Chung (115743)   +4 more
core   +1 more source